“Filgotinib - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Rheumatoid Arthritis in 7 Major Markets. A detailed picture of the FILGOTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Overview Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis. It was developed by the Belgian-Dutch biotech company Galapagos NV. The most common side effects include nausea, upper respiratory tract infection, urinary tract infection and dizziness. In August 2020, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA).
Scope of the report The report provides insights into: • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity. • Elaborated details on regulatory milestones and other development activities have been provided in this report. • The report also highlights the drug research and development activity details across the United States, Europe and Japan. • The report also covers the patents information with expiry timeline around Filgotinib. • The report contains forecasted sales for Filgotinib till 2030. • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Rheumatoid Arthritis. • The report also features the SWOT analysis with analyst insights and key findings of Filgotinib.
Methodology The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by our team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Filgotinib Analytical Perspective • In-depth Filgotinib Market Assessment This report provides a detailed market assessment of Filgotinib in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
• Filgotinib Clinical Assessment The report provides the clinical trials information of Filgotinib covering trial interventions, trial conditions, trial status, start and completion dates.
Report highlights • In the coming years, the market scenario for Rheumatoid Arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. • The companies and academics are working to assess challenges and seek opportunities that could influence Filgotinib dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition. • Other emerging products for Rheumatoid Arthritis are giving market competition to Filgotinib and launch of late-stage emerging therapies in the near future will significantly impact the market. • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Filgotinib. • Our in-depth analysis of the forecasted sales data of Filgotinib from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Filgotinib.
Key Questions • Which company is developing Filgotinib along with the phase of the clinical study? • What is the technology utilized in the development of Filgotinib? • What is the product type, route of administration and mechanism of action of Filgotinib? • What is the clinical trial status of the study and study completion date? • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Filgotinib development? • What are the key designations that have been granted to Filgotinib? • What is the forecasted market scenario of Filgotinib? • What is the history of Filgotinib and what is its future? • What is the forecasted sales of Filgotinib in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? • What are the other emerging products available and how these are giving competition to Filgotinib? • Which are the late-stage emerging therapies under development for the treatment of the PPD?
Our reports have been used by over 10K customers, including:
Atrial Fibrillation Surgery Market Research Report by Product (Catheter Ablation Product and Surgical Ablation Product), by Procedure (Catheter Ablation Procedures and Surgical Ablation Procedures) - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and forecast...
The global osteoarthritis therapeutics market is projected to reach USD 11.0 billion by 2025 from USD 7.3 billion in 2020, at a CAGR of 8.7% from 2020 to 2025. The growth of this market is driven significant adoption of pain medications, increasing prevalence of osteoarthritis, growing population susceptible to osteoarthritis, and rising number...
Diabetes Assays - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Diabetes Assays - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Diabetes Assays pipeline products with comparative analysis of the products at various stages...
120 pages •
By Infiniti Research Limited
• Dec 2020
Global Nasal Cannula Market 2020-2024 The analyst has been monitoring the nasal cannula market and it is poised to grow by $ 290.12 mn during 2020-2024 progressing at a CAGR of 8% during the forecast period. Our report on nasal cannula market provides a holistic analysis, market size and forecast, trends, growth drivers,...
The South & Central America kidney disease market is expected to reach US$ 9,060.9 million by 2027 from US$ 5,758.9 million in 2019. The market is estimated to grow with a CAGR of 5.9% from 2020 to 2027. The growth of this market is estimated attributed to the factors such as higher prevalence of kidney diseases in South & Central America...
Microalbuminuria Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Microalbuminuria Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Microalbuminuria Clinical trials scenario.This report provides top line data relating to the clinical trials...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.